Enhanced active efflux, repression of porin synthesis and development of Mar phenotype by diazepam in two enterobacteria strains

References

1. Alekshun M. N., Levy S. B. 1997; Regulation of chromosomally mediated multiple antibiotic resistance: the mar regulon. Antimicrob Agents Chemother 41:2067–2075
   [Google Scholar]
2. Balagué C., Vescovi E. G. 2001; Activation of multiple antibiotic resistance in uropathogenic Escherichia coli strains by aryloxoalcanoic acid compounds. Antimicrob Agents Chemother 45:1815–1822 [CrossRef]
   [Google Scholar]
3. Covelli V., Munno I., Decandia P., Altamura M., Cannuscio B., Maffione A. B., Jirillo E. 1991; Effects of benzodiazepines on the immune system. Acta Neurol (Napoli) 13:418–423
   [Google Scholar]
4. Doménech-Sánchez A., Martínez-Martínez L., Hernández-Allés S., Conejo M. C., Pascual A., Tomás J. M., Alberti S., Benedí V. J. 2003; Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance. Antimicrob Agents Chemother 47:3332–3335 [CrossRef]
   [Google Scholar]
5. Galdiero F., Bentivoglio C., Nuzzo I., Ianniello R., Capasso C., Mattera S., Nazzaro C., Galdiero M., Romano Carratelli C. 1995; Effects of benzodiazepines on immunodeficiency and resistance in mice. Life Sci 57:2413–2423 [CrossRef]
   [Google Scholar]
6. George A. M., Hall R. M., Stokes H. W. 1995; Multidrug resistance in Klebsiella pneumoniae : a novel gene, ramA , confers a multidrug resistance phenotype in Escherichia coli . Microbiology 141:1909–1920 [CrossRef]
   [Google Scholar]
7. Kern W. V., Oethinger M., Jellen-Ritter A. S., Levy S. B. 2000; Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli . Antimicrob Agents Chemother 44:814–820 [CrossRef]
   [Google Scholar]
8. Laschi A., Descotes J., Tachon P., Evreux J. C. 1983; Adverse influence of diazepam upon resistance to Klebsiella pneumoniae infection in mice. Toxicol Lett 16:281–284 [CrossRef]
   [Google Scholar]
9. Martínez-Martínez L., García I., Ballesta S., Benedí V. J., Hernández-Allés S., Pascual A. 1998; Energy-dependent accumulation of fluoroquinolones in quinolone-resistant Klebsiella pneumoniae strains. Antimicrob Agents Chemother 42:1850–1852
   [Google Scholar]
10. Martínez-Martínez L., Pascual A., Conejo M. C., García I., Joyanes P., Doménech-Sánchez A., Benedí V. J. 2002; Energy-dependent accumulation of norfloxacin and porin expression in clinical isolates of Klebsiella pneumoniae and relationship to extended-spectrum β-lactamase production. Antimicrob Agents Chemother 46:3926–3932 [CrossRef]
    [Google Scholar]
11. Mortimer P. G., Piddock L. J. 1993; The accumulation of five antibacterial agents in porin-deficient mutants of Escherichia coli. J Antimicrob Chemother 32:195–213
    [Google Scholar]
12. NCCLS 2003a; Methods for dilution susceptibility for bacteria that grow aerobically; approved standard. , 6th edn.M07–A6 Wayne, PA: National Committee for Clinical Laboratory Standards;
13. NCCLS 2003b; Performance standards for antimicrobial disk susceptibility tests; approved standard. , 8th edn.M02–A8 Wayne, PA: National Committee for Clinical Laboratory Standards;
14. Oethinger M., Kern W. V., Jellen-Ritter A. S., McMurry L. M., Levy S. B. 2000; Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump. Antimicrob Agents Chemother 44:10–13 [CrossRef]
    [Google Scholar]
15. Schneiders T., Amyes S. G. B., Levy S. B. 2003; Role of AcrR and RamA in fluoroquinolone resistance in clinical Klebsiella pneumoniae isolates from Singapore. Antimicrob Agents Chemother 47:2831–2837 [CrossRef]
    [Google Scholar]
16. Tavío M. M., Vila J., Ruiz J., Ruiz J., Martín-Sánchez A. M., Jiménez de Anta M. T. 1999; Mechanisms involved in the development of resistance to fluoroquinolones in Escherichia coli isolates. J Antimicrob Chemother 44:735–742 [CrossRef]
    [Google Scholar]